复方玄驹胶囊联合十一酸睾酮胶丸治疗少弱精子症的临床观察

目的研究复方玄驹胶囊联合十一酸睾酮胶丸治疗少弱精子症的临床疗效。方法将2012年12月—2013年11月中国人民解放军第306医院收治的120例少弱精子症患者,随机分为复方玄驹胶囊组（40例）、十一酸睾酮胶丸组（32例）和联合用药组（48例）。复方玄驹胶囊组口服复方玄驹胶囊,3粒/次,3次/d;十一酸睾酮胶丸组口服十一酸睾酮胶丸,1粒/次,2次/d;联合用药组口服复方玄驹胶囊和十一酸睾酮胶丸,用法用量同以上两组。1个月为1个疗程,共治疗4个疗程。对3组的临床疗效进行评价,同时对精液相关指标进行分析。结果复方玄驹胶囊组、十一酸睾酮胶丸组、联合用药组的总有效率分别为75.0%、68.8%、91.7%,联合用药组的有效率显著高于其他两组,差异均有统计学意义（P〈0.05）。治疗后,3组患者的精液量明显增多,精子存活率、a级精子比、（a＋b）级精子比、精子密度、向前精子活动率、直线运动速度、血清雄激素（T）水平、α-葡萄糖苷、精子顶体酶、果糖、精浆锌均较治疗前明显提高,同组治疗前后差异有统计学意义（P〈0.05）;且治疗后联合用药组高于其他两组,差异有统计学意义（P〈0.05）。治疗后,3组患者的精子液化时间、畸形精子率、血清FSH、LH、DNA碎片指数、精浆弹性蛋白酶均较治疗前显著下降,同组治疗前后差异有统计学意义（P〈0.05）;治疗后,联合用药组低于其他两组,差异有统计学意义（P〈0.05）。结论复方玄驹胶囊联合十一酸睾酮胶丸治疗少弱精子症有较好的临床疗效,可以改善精子相关指标,值得临床推广应用。

Clinical observation of Compound Xuanju Capsule combined with Testosterone Undecanoate Capsule in treatment of oligoasthenospermia

Objective To investigate the clinical efficacy of Compound Xuanju Capsule combined with Testosterone Undecanoate Capsule in the treatment of oligoasthenospermia. Methods Patients with oligoasthenospermia （120 cases） in the 306th Hospital of PLA from December 2012 to November 2013 were randomly divided into Compound Xuanju Capsule （40 cases）, Testosterone Undecanoate Capsule （32 cases）, and combined treatment （48 cases） groups. Patients in the Compound Xuanju Capsule group were po administered with Compound Xuanju Capsule, 3 grains/time, three times daily. Patients in the Testosterone Undecanoate Capsule group were po administered with Testosterone Undecanoate Capsule, 1 grain/time, twice daily. Patients in the combined treatment group were given Compound Xuanju Capsule and Testosterone Undecanoate Capsule, and the usage and dosage were the same with the above two groups. One month was as a period of treatment, and three groups were administered for three courses. The treatment efficacy was evaluated, while the related parameters of semen were analyzed. Results The efficacies on the patients in the Compound Xuanju Capsule, Testosterone Undecanoate Capsule, and combined treatment groups were 75.0%, 68.8%, and 91.7%, and the clinical efficacies in combined treatment group were higher than those in the other two groups with significant difference （P 〈 0.05）. After treatment, semen volume, sperm survival rate, a grade sperm ratio, （a ＋ b） sperm, sperm density, sperm activity rate, linear motion forward speed, the serum level of T, a-glucoside, sperm acrosome enzyme, fructose and seminal plasma zinc in three groups were improved obviously, and the differences were statistically significant before and after treatment in the same group （P 〈 0.05）. The results in the combined treatment group was higher than other two groups, and the difference was statistically significant （P 〈 0.05）. After treatment, liquefaction time, sperm deformity rate of sperm, serum FSH, LH, DNA fragmentation